ClinicalTrials.Veeva

Menu
C

Capital Nephrology | Greenbelt, MD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

MK-2060

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

1 of 1 total trial

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end s...

Active, not recruiting
End-Stage Renal Disease
End-Stage Kidney Disease
Drug: MK-2060
Drug: Placebo

Trial sponsors

Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems